血清 microRNAs 可预测慢性乙型肝炎患者对抗病毒治疗的反应。

Serum microRNAs predict response of patients with chronic hepatitis B to antiviral therapy.

机构信息

Hepatology and Cancer Biotherapy Ward/Department of Medical Oncology, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, PR China; Department of Infectious Diseases, Weifang People's Hospital, Weifang, Shandong 261000, PR China.

Laboratory of Cell and Molecular Biology and State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, PR China.

出版信息

Int J Infect Dis. 2021 Jul;108:37-44. doi: 10.1016/j.ijid.2021.05.015. Epub 2021 May 14.

DOI:10.1016/j.ijid.2021.05.015

PMID:33992764

Abstract

OBJECTIVES

To investigate the feasibility of using serum microRNAs to predict the response of chronic hepatitis B (CHB) patients to antiviral therapy over 48 weeks.

METHODS

Sixty-five CHB patients were divided into responder and non-responder groups according to whether hepatitis B e antigen seroconversion occurred at week 48. Serum microRNAs were dynamically detected.

RESULTS

At baseline, the responder group had lower miR-122-5p (P = 0.006) and higher miR-1307-3p (P = 0.018) than the non-responder group. After therapy, miR-320a-3p and miR-320c were higher in the responder group than the non-responder group (P = 0.043 and 0.031, respectively). In the responder group, 9 microRNAs-let-7d-5p, let-7f-5p, let-7i-5p, miR-126-3p, miR-1307-3p, miR-181a-5p, miR-21-5p, miR-425-5p and miR-652-3p-were significantly lower at week 48 than at baseline (P < 0.05); however, miR-320a-3p was significantly elevated after therapy (P < 0.001). In the non-responder group, miR-122-5p significantly decreased after therapy compared with baseline (P = 0.005). Finally, miR-122-5p was positively correlated with titer of hepatitis B virus DNA (r = 0.438, P = 0.008) and hepatitis B e antigen (r = 0.610, P < 0.001), and miR-320a-3p was negatively correlated with hepatitis B virus DNA titer (r = -0.366, P = 0.028) at baseline.

CONCLUSIONS

The dynamic fluctuations of serum microRNAs might predict the efficacy of antiviral therapy for CHB.

摘要

目的

研究血清 microRNAs 预测慢性乙型肝炎（CHB）患者抗病毒治疗 48 周应答的可行性。

方法

根据第 48 周乙型肝炎 e 抗原血清学转换情况，将 65 例 CHB 患者分为应答组和无应答组。动态检测血清 microRNAs。

结果

治疗前，应答组患者血清 miR-122-5p 水平低于无应答组（P = 0.006），miR-1307-3p 水平高于无应答组（P = 0.018）。治疗后，应答组 miR-320a-3p 和 miR-320c 高于无应答组（P = 0.043 和 0.031）。应答组有 9 个 microRNAs（let-7d-5p、let-7f-5p、let-7i-5p、miR-126-3p、miR-1307-3p、miR-181a-5p、miR-21-5p、miR-425-5p 和 miR-652-3p）在第 48 周时明显低于基线（P < 0.05）；而 miR-320a-3p 治疗后明显升高（P < 0.001）。无应答组 miR-122-5p 治疗后较基线明显下降（P = 0.005）。最后，miR-122-5p 与乙型肝炎病毒 DNA 载量（r = 0.438，P = 0.008）和乙型肝炎 e 抗原（r = 0.610，P < 0.001）呈正相关，miR-320a-3p 与乙型肝炎病毒 DNA 载量呈负相关（r = -0.366，P = 0.028）。